Can Aripiprazole Cause Parkinsonism? Two Cases with Aripiprazole-Induced Parkinsonism

The association between aripiprazole and Parkinsonism has not been well demonstrated. Our patients’ present complaints started several weeks after the initiation of aripiprazole only. We present two female cases who developed extrapyramidal syndrome (EPS) after administration of aripiprazole. Neither of them had ever used any antipsychotic agent except aripiprazole and the EPS disappeared within less than a week after administration of an anticholinergic drug. The severe Parkinsonism in our cases is associated with aripiprazole. Our report emphasizes the need for careful monitoring for the development of Parkinsonian features in patients treated with aripiprazole.

Aripiprazol Parkinsonizm sebebi olabilir mi? Aripiprazol ile Parkinsonizm gelişen iki olgu

Aripiprazol ve Parkinsonizm ilişkisi çok iyi gösterilememiştir. Olgularımızın yakınmaları sadece aripiprazol kullanımı ile ilaç başlandıktan bir kaç hafta sonra başlamıştır. Aripiprazol sonrası ekstrapiramidal sendrom (EPS) gelişen iki kadın olgu sunuyoruz. Bu olguların ikisinin de daha önce aripiprazol dışında hiç bir antipsikotik kullanımı yoktu ve EPS, antikolinerjik tedavi ile yaklaşık bir haftada geriledi. Olgularımızdaki ciddi Parkinsonizm aripiprazol ile ilişkilidir. Raporumuz aripiprazol başlanmış hastalarda Parkinsonian bulgu gelişimi açısından yakın izlem gerektiğini vurgulamaktadır.

PDF

___

Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short- term, placebo-controlled trials. Schizophr Res 2003; 61:123-136. [CrossRef]

Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, Seidl L. Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004; 19:1020-1028. [CrossRef]

McEvoy JP, Daniel DG, Carson WH Jr, McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 2007; 41:895-905. [CrossRef]

Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007; 13:13-24. [CrossRef]

Raj L, Mangla D. Aripiprazole induced severe parkinsonian symptoms - a case report. Indian J Psychiatry 2004; 46:174-175.

Lua LL, Zhang L. Development of Parkinsonism following exposure to aripiprazole: two case reports. J Med Case Rep 2009; 3:6448. [CrossRef]

Pasquier de Franclieu S, Germain C, Petitjean F. Aripiprazole induced Parkinsonism: a case report. Encephale 2009; 35:496- 498. (French) [CrossRef]

Rady A, El-Wafa H, Elkholy O. Severe aripiprazole-induced extrapyramidal Parkinsonian features in a patient with psychotic depression on sertraline: a case report. Internet J Ment Health 2010; 7:1-4.

Klein C, Westenberger A. Genetics of Parkinson’s Disease. Cold Spring Harb Perspect Med 2012; 2:a008888. [CrossRef]

Friedman JH, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J, Carson WH, Marcus RN. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s disease. Mov Disord 2006; 21:2078-2081. [CrossRef]

de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs. 2015; 29:773-799. [CrossRef]

Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 2005; 28:191- 208. [CrossRef]